Research Area: Infection Biological Activity: Atazanavir sulfate(BMS-232632-05) is a sulfate salt form of atazanavir (BMS-232632) that is an highly potent HIV protease inhibitor with an EC50 and EC90 of 2.6~5.3 nM and 9~15 nM in cell culture. Atazanavir (BMS-232632) is generally more potent than the five currently approved HIV-1 Prt inhibitors. Atazanavir (BMS-232632) inhibited the proteolytic cleavage of the viral gag precursor p55 polyprotein in a dose-dependent manner, with a EC50 of approximately 47 nM. Furthermore, Atazanavir (BMS-232632) is highly selective for HIV-1 Prt and exhibits cytotoxicity only at concentrations 6,500- to 23,000-fold higher than that required for anti-HIV activity. Atazanavir (BMS-232632) may be an effective HIV-1 inhibitor that may be utilized in a variety of different drug combinations. [1][2]References on Atazanavir sulfate[] ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 2000, 44:2093–2099[] Organic Process Research & Development, 2002, 6:323−328 |